FIELD: medicine.
SUBSTANCE: invention concerns a composition for the interleukin-4 cytokine gene silencing by means of an RNA interference mechanism, consisting of a cationic LTP peptide dendrimer described by formula (Arg)8(Lys)4(Lys)2Lys-Ala-Cys-NH2 used as a carrier, and two siRNA molecules described by formulas 5-UUGAUGAUCUCCUGUAAGGtt-3 and 5-AAAGAUGUCUGUUACGGUCtt-3.
EFFECT: creating the low-toxic composition used for interleukin-4 gene silencing.
3 cl, 18 dwg, 14 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION INHIBITING EXPRESSION OF INTERLEUKIN-4 AND INTERLEUKIN-13 GENES FOR THERAPY OF ALLERGIC RHINITIS | 2018 |
|
RU2710895C1 |
| METHOD FOR ALLERGIC BRONCHIAL ASTHMA TREATMENT, BASED ON CYTOKINES IL-4 AND IL-13 GENES EXPRESSION INHIBITION USING SIRNA MOLECULES | 2016 |
|
RU2615463C1 |
| METHOD FOR PREVENTING AND TREATING BRONCHIAL ASTHMA, COMPLICATING RESPIRATORY VIRAL INFECTIONS AND OTHER RESPIRATORY INFLAMMATORY DISEASES | 2012 |
|
RU2526146C2 |
| APPLICATION OF COMPOSITION CONSISTING OF CATIONIC LTP PEPTIDE AND MOLECULES OF RNA AGAINST RESPIRATORY VIRUSES | 2015 |
|
RU2609857C1 |
| MEAN FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS TO CELLS OF MAMMALS | 2014 |
|
RU2572575C1 |
| PEPTIDES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | 2020 |
|
RU2771605C2 |
| COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
| LABELLED DENDRIMER PEPTIDES | 2016 |
|
RU2611399C1 |
| METHOD FOR ASSESSMENT OF EFFICIENCY OF ALLERGEN-SPECIFIC IMMUNOTHERAPY IN ALLERGIC RHINITIS | 2019 |
|
RU2700788C1 |
| AGENT FOR INHIBITING THE EXPRESSION OF GENES ASSOCIATED WITH ACCUMULATION OF CHOLESTEROL BY HUMAN MACROPHAGES | 2018 |
|
RU2698199C1 |
